Drug or treatment

Enfortumab clinical trials

• 38Clinical trials
• 2New in 30 days
• 23Countries

Newest trials

All recruiting trials (38)

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• Ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin in untreated locally advanced or metastatic urothelial cancer

  This trial tests if adding ivonescimab to enfortumab vedotin works better than pembrolizumab plus enfortumab vedotin for people with untreated locally advanced or metastatic urothelial cancer.

  Recruiting at 2 sites Phase 2/3 Summit Therapeutics · Phoenix, Arizona and 6 other locations · NCT07815665

• Enfortumab Vedotin, Pembrolizumab, and Quemliclustat for unresectable or metastatic urothelial cancer

  This trial tests a three-drug combination to see if it can safely treat unresectable or metastatic urothelial cancer in adults.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07667335

• Enfortumab Vedotin plus Toripalimab vs Gemcitabine-Cisplatin as Neoadjuvant Therapy for Locally Advanced or High-Risk Muscle-Invasive Bladder Cancer

  This study tests if Enfortumab Vedotin with Toripalimab before surgery helps patients with locally advanced or high-risk muscle-invasive bladder cancer, compared with the standard Gemcitabine plus Cisplatin.

  Recruiting Phase 2 Peking University Third Hospital · Beijing, Beijing Municipality · NCT07647289

• Consolidative therapy after initial response in advanced bladder cancer

  This pilot trial tests adding radiation or surgery after a good response to EV + pembrolizumab in unresectable or oligometastatic muscle-invasive bladder cancer to see if residual disease can be eliminated or delayed from growing.

  Recruiting Phase 1/2 University of Washington · Seattle, Washington · NCT07579195

• Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer

  This trial tests whether combining enfortumab vedotin with pembrolizumab can help people with non-metastatic muscle-invasive bladder cancer keep their bladder and control the cancer better than standard concurrent chemoradiotherapy.

  Recruiting at 29 sites Phase 3 Astellas Pharma Inc · Little Rock, Arkansas and 28 other locations · NCT07566156

• GB-4362 combined with enfortumab vedotin and pembrolizumab for advanced urothelial cancer

  This study will test adding GB-4362 to enfortumab vedotin and pembrolizumab to see if it lowers treatment-related side effects like nerve damage in adults with advanced or metastatic urothelial cancer.

  Recruiting at 10 sites Phase 1 Generate Biomedicines · Duarte, California and 9 other locations · NCT07484022

• Enfortumab vedotin plus pembrolizumab to help people with muscle-invasive bladder cancer keep their bladder

  This trial tests whether giving enfortumab vedotin together with pembrolizumab can let people with muscle-invasive bladder cancer avoid bladder removal.

  Recruiting at 68 sites Phase 2 Astellas Pharma Inc · Little Rock, Arkansas and 67 other locations · NCT07475806

• PF-08634404 alone or with enfortumab vedotin for advanced urothelial (bladder) cancer

  This trial will try PF-08634404 by itself or together with enfortumab vedotin to see if it is safe and helps adults with advanced or metastatic urothelial (bladder) cancer.

  Recruiting at 173 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 183 other locations · NCT07421700

• Nerve effects of enfortumab vedotin in people with urothelial cancer

  We will see how nerve testing and patient-reported symptoms change in adults with urothelial cancer who are starting enfortumab vedotin.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07390617

• Enfortumab vedotin for advanced small bowel adenocarcinoma after platinum chemotherapy

  This trial tests whether enfortumab vedotin can shrink or control advanced small bowel adenocarcinoma in adults whose disease progressed on or who could not tolerate platinum-based chemotherapy.

  Recruiting at 3 sites Phase 2 National Cancer Center, Japan · Fukuoka and 2 other locations · NCT07347314

• Adding MK-3120 to enfortumab vedotin and pembrolizumab for advanced urothelial (bladder) cancer

  This study tests whether adding the investigational drug MK-3120 to standard enfortumab vedotin plus pembrolizumab helps people with locally advanced or metastatic urothelial (bladder) cancer.

  Recruiting at 17 sites Phase 1/2 Merck Sharp & Dohme LLC · San Francisco, California and 16 other locations · NCT07232602

• Pembrolizumab maintenance after initial enfortumab vedotin plus pembrolizumab for frontline metastatic urothelial cancer

  This trial will test whether continuing pembrolizumab after an 18-week course of enfortumab vedotin plus pembrolizumab helps people with previously untreated metastatic urothelial carcinoma.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07221942

• Vepugratinib with enfortumab vedotin and pembrolizumab for FGFR3‑altered advanced urothelial cancer

  This trial tests whether adding vepugratinib to enfortumab vedotin and pembrolizumab helps people with advanced or metastatic urothelial (bladder) cancer who have an FGFR3 genetic change, compared with placebo.

  Recruiting at 129 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 275 other locations · NCT07218380

• Enfortumab Vedotin in advanced endometrial cancer after prior treatments

  A Phase 2 study tests enfortumab vedotin in up to 12 adults with recurrent or metastatic endometrial cancer that has progressed after chemotherapy and immunotherapy.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07139977

• Enfortumab vedotin plus avelumab as first-line treatment for advanced penile cancer

  This trial tests whether combining enfortumab vedotin with avelumab helps men with advanced or metastatic penile squamous cell carcinoma as first-line treatment.

  Recruiting at 9 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Dresden and 8 other locations · NCT07110038

• Therapeutic plasma exchange plus enfortumab vedotin and pembrolizumab for bladder and upper urinary tract urothelial cancer

  This trial will test whether doing a therapeutic plasma exchange before giving enfortumab vedotin (an antibody‑drug conjugate) and pembrolizumab (an immune checkpoint inhibitor) helps people with metastatic or refractory urothelial (bladder or upper tract) cancer who have progressed on prior therapies.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07087860

• Gemcitabine plus carboplatin after progression on enfortumab vedotin and pembrolizumab for advanced urothelial cancer

  This trial tests whether the chemotherapy combination gemcitabine and carboplatin can shrink or control advanced urothelial cancer in people whose cancer got worse after enfortumab vedotin plus pembrolizumab.

  Recruiting at 2 sites Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania and 1 other locations · NCT07043972

• Testing Enfortumab Vedotin for Adenoid Cystic Carcinoma

  This study is testing if a new drug called enfortumab vedotin can help people with advanced adenoid cystic carcinoma feel better when other treatments aren't an option.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06891560

• Enfortumab vedotin for advanced urothelial (bladder) cancer in Indian adults

  This trial will test enfortumab vedotin given by IV infusion in Indian adults whose urothelial cancer has spread and progressed after prior treatments.

  Recruiting at 15 sites Phase 4 Astellas Pharma Inc · Patna, Bihar and 14 other locations · NCT06862219

• Combination treatment for muscle-invasive bladder cancer

  This study is testing a new combination of two medications to see if they can help people with muscle-invasive bladder cancer avoid surgery and improve their treatment outcomes.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · Duarte, California and 4 other locations · NCT06809140

• Combination of Enfortumab Vedotin and Pembrolizumab with Surgery for Advanced Bladder Cancer

  This study is testing if a combination of two medications, enfortumab vedotin and pembrolizumab, can help people with advanced bladder cancer before they have surgery.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT06764095

• Investigating nerve damage in patients treated for advanced bladder cancer

  This study is testing how the treatments enfortumab vedotin and pembrolizumab affect nerve damage and quality of life in people with advanced bladder cancer.

  Recruiting at 4 sites Comprehensive Cancer Center Munich (CCCM) · Augsburg, Bavaria and 3 other locations · NCT06657157

• Treatment with Enfortumab Vedotin for Advanced Colorectal and Liver Cancer

  This study is testing if a new drug called enfortumab vedotin can help adults with advanced colorectal or liver cancer who haven’t had success with other treatments.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06553885

• Combining enfortumab vedotin and pembrolizumab with radiation for muscle invasive bladder cancer

  This study is testing a new combination of a drug and radiation therapy to see if it helps people with muscle invasive bladder cancer who want to avoid surgery.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT06470282

• Combining enfortumab vedotin with radiation for advanced bladder cancer

  This study is testing whether combining a new drug called enfortumab vedotin with radiation can help people with advanced bladder cancer live longer and feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06434350

• Combining enfortumab vedotin with radiation for bladder cancer treatment

  This study is testing if combining a new drug called enfortumab vedotin with radiation can help patients with muscle invasive bladder cancer who can’t take standard chemotherapy before their surgery.

  Recruiting Phase 1/2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT06394570

• Neoadjuvant enfortumab vedotin plus pembrolizumab for cisplatin-eligible upper tract urothelial cancer

  This trial tests whether giving enfortumab vedotin with pembrolizumab before surgery helps people with high-grade, cisplatin-eligible upper tract urothelial cancer.

  Recruiting at 2 sites Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan and 1 other locations · NCT06356155

• Pembrolizumab plus enfortumab vedotin for collecting duct and renal medullary carcinoma

  This trial will test whether giving pembrolizumab together with enfortumab vedotin can shrink or control advanced or metastatic collecting duct carcinoma and renal medullary carcinoma in adults.

  Recruiting Phase 2 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT06302569

• Treatment for advanced penile squamous cell carcinoma using enfortumab vedotin

  This study tests if a new treatment called enfortumab vedotin can help people with advanced penile cancer live longer and feel better.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT06104618

• Enfortumab vedotin with or without pembrolizumab for rare testicular and urinary cancers

  This trial will try enfortumab vedotin alone or with pembrolizumab to see if they help people with rare bladder, urinary tract, or treatment‑resistant testicular cancers.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06041503

• Survey of Adults in South Korea with Urothelial Cancer Receiving PADCEV Injection

  This study looks at how well PADCEV Injection works and its side effects in adults with advanced urothelial cancer in South Korea over 48 weeks.

  Recruiting at 18 sites Astellas Pharma Inc · Goyang-si, Gyeonggi-do and 21 other locations · NCT06011954

• Combining pembrolizumab and enfortumab vedotin for treating high-risk upper tract urothelial cancer before and after surgery

  This study tests whether combining two cancer treatments, pembrolizumab and enfortumab vedotin, can help people with high-risk upper tract urothelial cancer before and after surgery.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT05775471

• Combination treatment for advanced bladder cancer

  This study is testing a new combination of two treatments for people with advanced bladder cancer to see if it helps them respond better and live longer.

  Recruiting at 4 sites Phase 2 Emory University · Atlanta, Georgia and 3 other locations · NCT05756569

• Combination therapy for high grade upper tract urothelial cancer patients refusing surgery

  This study is testing if a combination of two cancer drugs can help people with high grade upper tract urothelial cancer who don't want surgery live longer without their cancer getting worse.

  Recruiting at 2 sites Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Washington D.C., District of Columbia and 1 other locations · NCT05656235

• Combining cabozantinib and enfortumab vedotin for advanced bladder cancer

  This study is testing a new combination of two drugs, cabozantinib and enfortumab vedotin, to see if it can help people with advanced bladder cancer feel better and live longer.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT04878029

• Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial cancer

  This trial tests whether combining sacituzumab govitecan and enfortumab vedotin, with pembrolizumab in some patients, helps people with metastatic urothelial carcinoma who have progressed after platinum chemotherapy and PD‑1/PD‑L1 inhibitors.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04724018

Quick answers

How many clinical trials of Enfortumab are recruiting right now?

38, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 23 countries. The most sites are in United States (30 trials), Germany (5 trials), South Korea (5 trials), China (4 trials), Japan (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 1/2: 8, Phase 4: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →